NYSE:WST - West Pharmaceutical Services Stock Price, Forecast & News

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services declared a quarterly dividend on Tuesday, December 17th. Investors of record on Wednesday, January 22nd will be given a dividend of $0.16 per share on Wednesday, February 5th. This represents a $0.64 annualized dividend and a yield of 0.41%. The ex-dividend date is Tuesday, January 21st. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.15. View West Pharmaceutical Services' Dividend History.

West Pharmaceutical Services declared that its Board of Directors has approved a stock repurchase plan on Thursday, February 15th 2018, which authorizes the company to repurchase 800,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's management believes its shares are undervalued.

West Pharmaceutical Services Inc. (NYSE:WST) posted its quarterly earnings data on Thursday, October, 24th. The medical instruments supplier reported $0.79 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.71 by $0.08. The medical instruments supplier had revenue of $456.10 million for the quarter, compared to analysts' expectations of $450.03 million. West Pharmaceutical Services had a return on equity of 16.66% and a net margin of 12.82%. The company's revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.76 earnings per share. View West Pharmaceutical Services' Earnings History.

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for West Pharmaceutical Services.

West Pharmaceutical Services issued an update on its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share (EPS) guidance of $3.10-3.15 for the period, compared to the Thomson Reuters consensus estimate of $3.06. The company issued revenue guidance of $1.815-1.825, compared to the consensus revenue estimate of $1.81 billion.

3 analysts have issued twelve-month price objectives for West Pharmaceutical Services' shares. Their forecasts range from $112.16 to $135.00. On average, they expect West Pharmaceutical Services' share price to reach $123.05 in the next twelve months. This suggests that the stock has a possible downside of 21.9%. View Analyst Price Targets for West Pharmaceutical Services.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for West Pharmaceutical Services.

Press coverage about WST stock has been trending very negative this week, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. West Pharmaceutical Services earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for West Pharmaceutical Services.

West Pharmaceutical Services saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,340,000 shares, an increase of 25.2% from the December 15th total of 1,070,000 shares. Based on an average trading volume of 419,200 shares, the days-to-cover ratio is currently 3.2 days. Currently, 1.8% of the shares of the stock are sold short. View West Pharmaceutical Services' Current Options Chain.

Some companies that are related to West Pharmaceutical Services include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Anika Therapeutics (ANIK), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include Johnson & Johnson (JNJ), Mcdonald's (MCD), PepsiCo (PEP), Lowe's Companies (LOW), Medtronic (MDT), NVIDIA (NVDA), AFLAC (AFL), PPG Industries (PPG), Sherwin-Williams (SHW) and Stryker (SYK).

West Pharmaceutical Services' stock is owned by many different of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (0.80%), Nisa Investment Advisors LLC (0.10%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.02%) and IFM Investors Pty Ltd (0.01%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

WST stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Riverbridge Partners LLC and First Hawaiian Bank. View Insider Buying and Selling for West Pharmaceutical Services.

WST stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, IFM Investors Pty Ltd, State of Alaska Department of Revenue, Wedbush Securities Inc., Sciencast Management LP, Cerebellum GP LLC, Huntington National Bank and Louisiana State Employees Retirement System. View Insider Buying and Selling for West Pharmaceutical Services.

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WST stock can currently be purchased for approximately $157.59.

West Pharmaceutical Services has a market capitalization of $11.66 billion and generates $1.72 billion in revenue each year. The medical instruments supplier earns $206.90 million in net income (profit) each year or $2.81 on an earnings per share basis. West Pharmaceutical Services employs 7,700 workers across the globe.View Additional Information About West Pharmaceutical Services.

The official website for West Pharmaceutical Services is http://www.westpharma.com/.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]